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Abstract
Background: Cirrhosis and severe sepsis are factors associated with increased mortality in intensive care unit (ICU),
but chronic hepatitis C (CHC) has been less studied in ICU. The aim of this study was to analyze the impact of CHC
on the mortality of cirrhotic patients admitted to ICU according to severe sepsis and decompensated cirrhosis.
Methods: We carried out a retrospective study based on CHC-cirrhotic patients (CHC-group) admitted to ICU
(n = 1138) and recorded in the Spanish Minimum Basic Data Set (2005–2010). A control-group (randomly selected
cirrhotic patients without HIV, HBV, or HCV infections) was also included (n = 4127). The primary outcome variable
was ICU mortality. The cumulative mortality rate on days 7, 30, and 90 in patients admitted to the ICUs was
calculated by dividing the number of deaths by the number of patients admitted to the ICU. The adjusted hazard
ratio (aHR) for death in the ICU was estimated through a semi-parametric Bayesian model of competing risk.
Results: The CHC-group had a higher cumulative incidence of severe sepsis than the control-group in compensated
cirrhosis (37.4 vs. 31.1 %; p = 0.024), but no differences between the CHC-group and the control-group in decompensated
cirrhosis were found. Moreover, a higher cumulative incidence of severe sepsis was associated with decompensated
cirrhosis compared to compensated cirrhosis in the control-group (40.1 vs. 31.1 %; p < 0.001) whereas this was not
observed in the CHC group (38.1 vs. 37.4 %; p = 0.872). The CHC-group had higher cumulative mortality than the
control-group by days 7 (47 vs. 41.3 %; p < 0.001), 30 (78.5 vs. 73.5 %; p < 0.001), and 90 (96.3 vs. 95.9 %; p < 0.001). In a
competitive risk model, the CHC-group had a higher risk of dying if the ICU course was complicated by severe sepsis
(adjusted hazard ratio (aHR) = 1.19; p = 0.003), but no significant values in patients with absence of severe sepsis were
found (aHR = 1.09; p = 0.068). When patients were stratified by cirrhosis stage and severe sepsis, CHC patients with
compensated cirrhosis had the higher risk of death if they had severe sepsis (aHR = 1.35; p = 0.002). Moreover, the
survival was low in patients with decompensated cirrhosis and severe sepsis but we did not find significant differences
between CHC-group and control-group.
Conclusions: CHC was associated with an increased risk of death in cirrhotic patients admitted to ICUs, particularly in
patients with compensated cirrhosis and severe sepsis.
Keywords: Critical care, Survival, Chronic hepatitis C, Severe sepsis, HCV
* Correspondence: sresino@isciii.es
†Equal contributors
2Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología,
Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
7Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus
Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2, 28220
Majadahonda, Madrid, Spain
Full list of author information is available at the end of the article
© 2016 Álvaro-Meca et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Álvaro-Meca et al. BMC Infectious Diseases  (2016) 16:122 
DOI 10.1186/s12879-016-1448-8
Background
Hepatitis C virus (HCV) is an important cause of liver
disease worldwide and constitutes a major global public-
health threat. About 9 million people have chronic hepa-
titis C (CHC) in the European region (3 % population)
and 350,000 deaths occur each year as a result of HCV
infections [1]. CHC is associated with an increased risk
of hospital admission and mortality due to severe liver
disease, cirrhosis, end-stage liver disease, and other con-
ditions [2–4]. This increased mortality rate remains des-
pite the administration of the HCV-specific treatment of
peg-interferon/ribavirin [5]. However, new direct anti-
viral agents against HCV mark the beginning of an
extraordinary new era in HCV therapy, which will lead
to viral eradication in most if not all CHC patients who
undergo treatment [6, 7]. A virological cure improves
quality of life and reduces the risk of hepatic decompen-
sation events and liver-related deaths [8].
Hepatitis C is associated with increased mortality as
HCV-infected individuals have a higher all-cause and a
higher liver-related mortality rate compared to the gen-
eral population [9]. Cirrhosis is a common comorbid
condition that complicates the management of patients
admitted to an intensive-care unit (ICU) [10], and is as-
sociated with increased mortality [11]. In addition, a sig-
nificant proportion of patients develop decompensated
cirrhosis and extra-hepatic organ dysfunction [12].
Moreover, bacterial infections are very common in cir-
rhotic patients [13] and severe sepsis is more likely to
occur in individuals with severe liver disease [14, 15].
Bacterial infections and sepsis represent the most im-
portant causes of progressive liver failure, development
of liver-related complications, and increased mortality in
cirrhotic patients [12, 15]. This susceptibility to infection
is caused, at least in part, by defects in the host’s defense,
which manifests as “sepsis-like” immune paralysis with
reduced cellular immune function [16, 17].
The aim of this study was to analyze whether cirrhotic
patients with CHC have a greater tendency to die in
ICU than non-CHC cirrhotic subjects through the use
of comprehensive records of the Minimum Basic Data
Set (MBDS) in Spain.
Methods
Study design and data source
A retrospective study with nationwide population-based
diagnoses from the Spanish MBDS was performed. We
identified all consecutive cirrhotic patients with a record
of CHC (CHC-group) and aged >18 years who were ad-
mitted to ICUs in Spanish hospitals between January 1,
2005 and December 31, 2010. A control-group of cirrhotic
patients without CHC was selected at a proportion of 4:1
with regards to the CHC-group. This control-group con-
tained patients aged >18 years and admitted to the ICU
with no record of being tested for HCV, HIV, or HBV;
they were randomly selected according to the same fre-
quencies of age, gender, trauma and surgical conditions,
and comorbidities (see Additional file 1: Supplementary
Digital Content (SDC)-Appendix 1-6) as occurred in the
CHC-group [18].
Data were obtained from records in the MBDS of the
National Surveillance System for Hospital Data in Spain,
provided by the Spanish Ministry of Health. The MBDS
is a clinical and administrative database containing
clinical information recorded at the time of hospital
discharge, which has an estimated coverage of total
admissions to public hospitals of 97.7 % [19]. The MBDS
provides the encrypted patient identification number,
gender, date of birth, dates of hospital admission and
discharge, medical institutions providing the services,
the diagnosis and procedure codes according to the
International Classification of Diseases 9th edn, Clinical
Modification (ICD-9-CM), as well as the outcome at dis-
charge [20].
Length of stay was obtained as the difference, in days,
between the date of hospital admission and date of dis-
charge or death in the ICU. The day of hospital admis-
sion was considered as day 0. Discharge on the same day
was considered as a 1-day stay. For patients admitted
several times to the ICU, only the first admission (also
called the index episode) was analyzed.
The data were treated with full confidentiality accord-
ing to Spanish legislation. MBDS is regulated by an law,
which explains how institutions have to proceed with
health-related personal data. Informed consent is not re-
quired because personal data are collected for official
usage by public administrations. The study was approved
by the Research Ethics Committee (Comité de Ética de
la Investigación y de Bienestar Animal) of the Instituto
de Salud Carlos III (Madrid, Spain).
Study groups and ICD-9-CM codes selected
We included patients admitted to an ICU and who were
coded in the MBDS. Then, we selected all patients with
a cirrhosis diagnosis at the time of hospital discharge,
both compensated and decompensated. According to
MDBS characteristics, we cannot affirm that all patients
had a cirrhosis diagnosis at hospitalization day, but prac-
tically we may assume that all patients had cirrhosis
when they entered the hospital because cirrhosis is de-
veloped over years. Patients with liver cancer or with a
liver transplant were excluded (see Additional file 1:
SDC-Appendix 2).
The ICD-9-CM codes were also used to define viral-
infection status (see Additional file 1: SDC-Appendix 3):
i) HIV infection (042 or V08); ii) chronic HCV infection
(ICD-9-CM codes 070.44, 070.54, 070.7x, or V02.62); or
iii) chronic HBV infection (ICD-9-CM codes 070.2x,
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070.3x, or V02.61). Next, we established two groups of
patients according to their viral status: i) control-
group (patients randomly selected without HIV, HBV,
or HCV infections); ii) CHC-group (patients exclu-
sively infected with HCV [both HBV and HIV infec-
tions were excluded]).
Severe sepsis was defined by the presence of an
infection-associated diagnosis and organ dysfunction ac-
cording to the criteria of Angus et al. [21], using ICD-9-
CM codes (see Additional file 1: SDC-Appendix 4 and 5).
The MBDS provides the ICD-9-CM codes for the Angus
criteria, but not the date of diagnoses: thus, we were un-
able to calculate the date of onset of severe sepsis, which
was recorded simply as present or absent during the hos-
pital stay.
Factors and outcome variables
The main factors of study were the HCV serostatus
(CHC-group vs. control-group) and type of cirrhosis
(compensated vs. decompensated). The outcome vari-
ables were the onset of severe sepsis and death.
Statistical analyses
For descriptive analysis, the results are presented as me-
dians and their interquartile ranges for continuous vari-
ables; and as absolute numbers and percentages for
categorical data. Categorical data and proportions were
analyzed using chi-squared test or Fisher’s exact test, as
required. Student’s t-test or the Mann–Whitney U tests
were used to compare continuous variables.
The primary outcome variable was ICU mortality. The
cumulative mortality rate on days 7, 30, and 90 in
patients admitted to the ICUs was calculated without
considering censoring. This rate was estimated by
dividing the number of deaths by the number of patients
admitted to the ICU. Log-linear modeling for contin-
gency tables was used to estimate the main and inter-
action (moderator) effects independently.
We also calculated the probability of death, after tak-
ing censoring into account, using a semi-parametric
model of competing risk to prevent the results being
biased [22]. This analysis determined the effect of CHC
on the risk of ICU mortality according to the presence
of severe sepsis: I.e., a) risk of ICU mortality in patients
with severe sepsis; and b) risk of ICU mortality in pa-
tients without severe sepsis. The model was adjusted by
the following covariates: age, gender, decompensated cir-
rhosis, Charlson comorbidity index, abuse of alcohol
and/or drugs, number of organ failures, and site of infec-
tion (see Additional file 1 SDC). This semi-parametric
model provided the survival probabilities and adjusted
hazard ratios (aHR).
All analyses were performed using the R statistical
package, version 3.1.0 (GNU General Public License)
[23] and BayesX software version 2.1 (GNU General
Public License) [24]. All tests were two-tailed, with
p-values of <0.05 considered statistically significant.
Results
Patients’ characteristics
Table 1 shows the epidemiological and clinical character-
istics of cirrhotic patients included in this study: 4127 pa-
tients in the control-group and 1138 in the CHC-group.
Overall, the epidemiological and clinical characteristics of
the two groups of subjects were quite similar. The most
clinically significant differences between groups were a
lower length of hospital stay (p < 0.001), less abuse of alco-
hol and/or drugs (p < 0.001), and a lower Charlson comor-
bidity index (p < 0.001) in the CHC group compared to
the control group. Conversely, the CHC group exhibited a
higher frequency of decompensated cirrhosis (p < 0.001).
Severe sepsis in cirrhotic patients admitted into ICUs
Table 2 shows that severe sepsis in the CHC-group and
controls had a similar cumulative incidence (37.9 vs.
36.6 %; p = 0.456). Respiratory failure was the most com-
mon organ failure and the digestive tract was the most
common site of infection in both groups.
Table 1 Epidemiological and clinical characteristics of cirrhotic
patients admitted into Spanish intensive care units between
2005 and 2010
Control-group CHC-group p-value
No. 4127 1138
Males 2737 (66.3 %) 719 (63.2 %) 0.053
Age (years) 57.2 (56.7; 57.6) 58.2 (57.4; 58.9) 0.030
Length of hospital
stay (days)
12.5 (11.9; 13.1) 10.7 (9.9; 11.6) <0.001
Abuse of alcohol
and drugs
1622 (39.3 %) 342 (30.1 %) <0.001
Charlson comorbidity
index
0.91 (0.86; 0.95) 0.75 (0.68; 0.82) <0.001
Decompensated
cirrhosis
2539 (61.5 %) 777 (68.3 %) <0.001
General comorbidities
Cardiovascular 3041 (73.7 %) 830 (72.9 %) 0.638
Infectious without
hepatitis
1352 (32.8 %) 383 (33.7 %) 0.594
Respiratory 2212 (53.6 %) 597 (52.5 %) 0.517
Gastrointestinal/hepatic 4029 (97.6 %) 1105 (97.1 %) 0.368
Neurological 911 (22.1 %) 263 (23.1 %) 0.482
Cancer 296 (7.2 %) 93 (8.2 %) 0.281
Diabetes 692 (16.8 %) 210 (18.5 %) 0.196
Values are expressed as absolute numbers (percentages) and as the mean
(95 % confidence intervals). P-values were calculated by the chi-squared test
or Student’s t-test, as appropriate
Abbreviation: CHC chronic hepatitis C virus
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Table 3 shows the cumulative incidence of severe
sepsis in cirrhotic patients after stratifying patients by
type of cirrhosis (compensated or decompensated). The
CHC-group had a higher cumulative incidence of severe
sepsis than the control-group in compensated cirrhosis
(37.4 vs. 31.1 %; p = 0.024), but no differences between
the CHC-group and the control-group in decom-
pensated cirrhosis were found. Moreover, a higher cu-
mulative incidence of severe sepsis was associated with
decompensated cirrhosis compared to compensated cir-
rhosis in the control-group (40.1 vs. 31.1 %; p < 0.001)
whereas this was not observed in the CHC group (38.1
vs. 37.4 %; p = 0.872).
Cumulative crude mortality rate in patients admitted to
the ICU
Overall, the CHC-group had a higher ICU mortality rate
than the control-group at days 7 (47 vs 41.3 %; p = 0.001),
30 (78.5 vs. 73.5 %; p = 0.001), and 90 (85.4 vs.
82.8 %; p = 0.038) (Fig. 1a). When stratified for severe
sepsis, the CHC-group still had higher ICU mortality rates
than the control-group at days 7 (43.9 vs. 34 %; p < 0.001)
and 30 (87.5 vs. 79 %; p < 0.001), but no significant dif-
ferences between the CHC-group and control-group in
patients without severe sepsis were found (Fig. 1b and c).
When stratified by cirrhosis stage, the CHC-group
with compensated cirrhosis had a higher rate of ICU
mortality than the control-group at days 7 (50.7 vs.
40.9 %; p = 0.001), 30 (77 vs. 68.5 %; p = 0.002), and 90
(81.4 vs. 75 %; p = 0.012), but no significant differences be-
tween the CHC-group and the control-group in patients
with decompensated cirrhosis were found (Fig. 1d and e).
Estimated risk of death in patients admitted to the ICU
The CHC-group had lower estimated survival in the
ICUs compared to the control-group, especially in
patients with severe sepsis (Fig. 2a1). Thus, the CHC-
group had a higher risk of dying if the ICU course was
complicated by severe sepsis (aHR = 1.19; p = 0.003), but
no significant values in patients with absence of severe
sepsis were found (aHR = 1.09; p = 0.068) (Fig. 3). When
patients were stratified by cirrhosis stage and severe sep-
sis, the CHC-group had lower survival compared to the
control-group in patients with compensated cirrhosis
and severe sepsis (Fig. 2A2). No significant differences
between the CHC-group and the control-group were
found in the other strata (Fig. 2b2-a3-b3). Thus, CHC
patients with compensated cirrhosis had the higher risk
of death if they had severe sepsis (aHR = 1.35; p = 0.002)
(Fig. 3). Moreover, the survival was low in patients with
decompensated cirrhosis and severe sepsis but we did
not find significant differences between the CHC-group
and the control-group (Fig. 2a3). Thus, patients in the
CHC-group with decompensated cirrhosis had not a sig-
nificant risk of dying compared with the control-group,
independently of the onset of severe sepsis (Fig. 3).
Discussion
Cirrhosis and mortality have been widely studied in individ-
uals admitted to ICUs [10, 11, 15, 25, 26]; but to our know-
ledge, no previous studies have investigated the influence of
CHC on ICU mortality among cirrhotic patients. Our
manuscript provides a nationwide view of mortality rates of
Table 2 Cumulative incidence of severe sepsis in cirrhotic
patients admitted to intensive-care units between 2005
and 2010
Control-group CHC-group p-value
Severe sepsis 1511 (36.6 %) 431 (37.9 %) 0.456
Acute organ dysfunction
Respiratory 1329 (88 %) 365 (84.7 %) 0.963
Cardiovascular 1018 (67.4 %) 283 (65.7 %) 0.920
Renal 1036 (68.6 %) 288 (66.8 %) 0.919
Hematological 469 (31 %) 124 (28.8 %) 0.697
Metabolic 254 (16.8 %) 84 (19.5 %) 0.154
Neurological 222 (14.7 %) 43 (10 %) 0.035
Hepatic 556 (36.8 %) 146 (33.9 %) 0.606
Site of infection
Respiratory 515 (34.1 %) 157 (36.4 %) 0.259
Digestive 896 (59.3 %) 267 (61.9 %) 0.222
Genitourinary 171 (11.3 %) 46 (10.7 %) 0.946
Central nervous system 16 (1.1 %) 9 (2.1 %) 0.132
Skin, soft tissue, or bone 87 (5.8 %) 33 (7.7 %) 0.141
Circulatory 39 (2.6 %) 8 (1.9 %) 0.555
Values are expressed as absolute numbers (percentages). P-values were
calculated using the chi-squared test. The sum of sites of infection is greater
than the number of patients with severe sepsis because a patient may have
more than one site of infection
Abbreviation: CHC chronic hepatitis C virus
Table 3 Cumulative incidence of severe sepsis in cirrhotic patients admitted to intensive-care units between 2005 and 2010
according to the absence or presence of decompensated cirrhosis
All patients Control-group CHC-group p-values
Compensated cirrhosis 629 (32.3 %) 494 (31.1 %) 135 (37.4 %) 0.024
Decompensated cirrhosis 1313 (39.6 %) 1017 (40.1 %) 296 (38.1 %) 0.349
p-values <0.001 <0.001 0.872
Values are expressed as absolute counts (percentages). P-values were calculated using the chi-squared test
Abbreviation: CHC chronic hepatitis C
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CHC-cirrhotic patients admitted into ICUs in Spain. In this
study, the major findings were: 1) patients with CHC had a
higher cumulative incidence of severe sepsis compared to
patients without CHC in the subgroup of compensated cir-
rhosis, whereas the cumulative incidence of severe sepsis
did not differ among patients with decompensated cirrho-
sis; 2) cirrhotic patients with CHC (CHC-group) had a
greater tendency to die in ICU than non-CHC subjects
(control-group); 3) The influence of CHC was observed on
patients with compensated cirrhosis and severe sepsis,
whereas CHC seemed to have no impact on mortality in
patients with decompensated cirrhosis, independently of
the onset of severe sepsis. Note that several baseline
clinical characteristics showed statistically significant dif-
ferences between groups, but these variables were in-
cluded in the model to adjust the competitive risks.
There is controversial about whether patients with cirrho-
sis may benefit from the ICU management. In our study,
the mortality was extremely high (merely 80 %) in compari-
son to data reported in the review of Saliba et al. [18]. There
also are several important series published during the last
5 years with a mortality about 50 % [59 % Das et al. [27],
70.1 % Galbois et al. [28], 58.8 % Pan et al. [29], 68.1 % Bao
et al. [30], 60 % McPhail et al. [31]]. These differences in
death rates could be due to the designs of the studies used
to obtain the data, which were very different, especially in
Fig. 1 Cumulative crude mortality rates by days 7, 30, and 90 of cirrhotic patients admitted to Spanish ICUs between 2005 and 2010. Values are
expressed as absolute counts (percentages). P-values were calculated using the chi-squared test. Abbreviations: ICU intensive-care unit, CHC chronic
hepatitis C. (a) All patients; (b), Patients with severe sepsis; (c), Patients without severe sepsis; (d), Patients with compensated cirrhosis; (e), Patients with
decompensated cirrhosis
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our study carried out with data of Spanish MBDS from
2005 to 2010 and with a higher number of patients.
A systemic response to infection is more intense in
the presence of cirrhosis, which translates into a greater
risk of developing severe sepsis [14]. Thus, cirrhotic pa-
tients admitted into ICUs, apart from having a higher
prevalence of infection than non-cirrhotic patients, have
a higher rate of sepsis and death [13]. Furthermore, de-
compensated cirrhosis predisposes to delayed intestinal
transit, increasing intestinal permeability and facilitating
bacterial translocation from the gastro-intestinal lumen
to the systemic circulation. This is accompanied by
cirrhosis-associated immune dysfunction, which encour-
ages systemic inflammation [32]. In our study, cirrhotic
patients with and without CHC had similar rates of
severe sepsis. However, when patients were stratified by
the presence or absence of decompensated cirrhosis, the
CHC-group with compensated cirrhosis had a higher cu-
mulative incidence of severe sepsis than expected; which
suggests that, in patients with compensated cirrhosis,
susceptibility to severe sepsis may be increased by CHC.
The severity of infection is higher in cirrhotic patients
than in non-cirrhotic patients [12, 15]. In addition, infec-
tions are increasingly recognized as a major trigger of
systemic inflammation and organ failure in decompen-
sated cirrhosis, leading to four-fold increased mortality
rates [33]. In this setting, bacterial infections and sepsis
are recognized as a distinct stage in the natural progres-
sion of chronic liver disease as they accelerate organ
failure and contribute to the high mortality observed in
decompensated cirrhosis [32]. In our study, as expected,
cirrhotic patients with severe sepsis had a higher risk of
ICU mortality than patients without severe sepsis; and
patients with decompensated cirrhosis had a higher risk
Fig. 2 Estimated survival of cirrhotic patients admitted to intensive-care units (ICU) between 2005 and 2010. Survival functions were calculated
using a competing risk model (see Statistical analyses section). Abbreviations: CHC chronic hepatitis C. (a) Patients with severe sepsis; (b), Patients
without severe sepsis; (A1), Patients with severe sepsis and compensated cirrhosis; (A2), Patients without severe sepsis and compensated cirrhosis;
(B1), Patients with severe sepsis and decompensated cirrhosis; (B2), Patients without severe sepsis and decompensated cirrhosis
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of ICU mortality compared to patients with compen-
sated cirrhosis, independently of CHC status. During
cirrhosis, sepsis is accompanied by a markedly imbal-
anced cytokine response with increased tissue damage
and inflammation [14]. Moreover, patients with end-
stage liver disease have enhanced intestinal permeability
and translocation of bacteria and their products, imbal-
anced immune response, and aggravated intrahepatic
microcirculatory dysfunction, which causes accumu-
lation of toxins and immune dysfunction that may per-
petuate end-stage organ dysfunction [34], and may
explain the higher mortality rates [35].
As discussed above, HCV infection is a major cause of
cirrhosis [36], and cirrhotic patients in ICUs have higher
risks of sepsis and death, particularly in end-stage liver
disease [15]. In our study, CHC appears to be a key fac-
tor that increases the risk of death in compensated cir-
rhotic patients with severe sepsis in ICUs, but the effect
of CHC status was not maintained in other patients with
compensated cirrhosis/non-severe sepsis or patients with
decompensated cirrhosis (with or without severe sepsis).
However, we have no clear explanation for this effect ob-
served exclusively in patients with compensated cirrhosis
and severe sepsis. On the one hand, CHC-associated co-
morbidities could promote negative clinical outcomes
among cirrhotic patients, thus causing a significant pro-
portion of the mortalities of CHC patients [37]. On the
other hand, persistent HCV infection is the result of a
series of connected events that culminate in diminished
immunity and the inability to eliminate HCV infection
[38]. This immune dysfunction is accompanied by in-
flammation and immune activation during CHC [38],
which could be crucial in the prognosis of CHC-
cirrhotic patients. Thus, it could be possible that CHC
increases the immune dysfunction that occurs with severe
sepsis, worsening the prognosis of cirrhotic patients. In
this context, the effect of CHC could be diluted in the
presence of decompensated cirrhosis in patients with a
more advanced stage of disease, thus resulting in a worse
prognosis, whereas the effect of CHC could be clearly ob-
served in patients with compensated cirrhosis, as observed
in our study.
Several points should be taken into account for the
correct interpretation of our results (Limitations of the
study):
Firstly, this study was retrospective and the acquisition
of some clinical data related to HCV infection (viral sta-
tus, patients who received prior treatment by antivirals,
etc.) and the ICU (community acquired or nosocomial
nature of the sepsis, or prognostic scores such as Child-
Pugh, MELD, SOFA or CLIF-SOFA score) were unavail-
able from the MBDS records. Furthermore, we do not
know the reason for admission of these patients; there-
fore, the prognostic could have been different if the pa-
tients were admitted for gastrointestinal bleeding, or for
severe sepsis or septic shock. Neither do we know if
these patients were admitted due to severe sepsis or ac-
quired the sepsis in the ICU prior to death.
Secondly, the time until death or discharge was calcu-
lated from entry into the hospital rather than the ICU be-
cause the date of ICU admission was not recorded in the
MBDS. A time bias could have occurred [37], since some
patients may have been admitted directly into an ICU
whereas others may have had a period of time between
hospital admission and entry into an ICU, and this time
period was included in the observation time. However,
this theoretical bias should be well-balanced between the
groups, and should only affect survival time.
Fig. 3 Adjusted risk of death of cirrhotic patients with chronic hepatitis C admitted to intensive-care units (ICU) between 2005 and 2010, compared to
a control-group. Adjusted hazard ratios were calculated by a competing risk model (see Statistical analyses section). Abbreviations: aHR adjusted hazard
ratio, 95 % CI 95 % confidence interval, SS severe sepsis, Non-SS non-severe sepsis, CC compensated cirrhosis, DC decompensated cirrhosis
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Thirdly, due to the use of the administrative databases,
was the inaccuracy in differentiating the etiologies of the
diseases and the reporting of organ dysfunction, which
could have engendered a confusion bias. In this context,
grouping of ICD-9-CM codes into comorbidities, organ
dysfunction, and site of infection (Additional file 1:
SDC-Appendixes 1–6) may have been the best approach
to solve this issue. On the other hand, MBDS has already
proven its usefulness in the previous assessments of out-
comes among patients admitted to ICU [39, 40]. This
database has advantages being a national clinical admin-
istrative database, which allows analyze the trends in
important public health issues.
Conclusions
CHC was associated with an increased risk of death in
cirrhotic patients admitted to ICUs, particularly in pa-
tients with compensated cirrhosis and severe sepsis.
Additional file
Additional file 1: Appendix 1. International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM) codes for comorbid diseases.
Appendix 2. International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes for CHC related diagnoses and abuse of
alcohol and drugs. Appendix 3. International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM) codes for HIV, HCV and HBV status.
Appendix 4. International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes for acute organ dysfunction. Appendix 5.
International Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) codes for bacterial and fungal infections. Appendix 6.
International Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) coding algorithms for Charlson comorbidities. (DOC 219 kb)
Abbreviations
HCV: hepatitis C virus; CHC: chronic hepatitis C; ICU: intensive care unit;
MBDS: minimum basic data set; ICD-9-CM: International Classification of
Diseases, 9th ed, Clinical Modification; SDC: supplementary digital content;
CHC-group: patients exclusively infected with HCV; Control-group: patients
randomly selected without HIV, HBV, or HCV infections; aHR: adjusted
hazard ratio.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AAM participated in the study concept, design, statistical analysis, and
drafting of the manuscript. MAJS participated in the study concept, design,
and drafting of the manuscript. AB participated in the drafting of manuscript
and performed a critical revision for intellectual content. JM participated in
the drafting of manuscript and performed a critical revision for intellectual
content. HR participated in statistical analysis, and performed a critical
revision for intellectual content. TK participated in statistical analysis, and
performed a critical revision for intellectual content. SR conceived of the
study, participated in its design and coordination, and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We would like to thank the “Subdirección General del Instituto de
Información Sanitaria (Ministerio de Sanidad, Servicios Sociales e Igualdad)”
for providing the information on which this study was based.
Funding
This research has been supported by Instituto de Salud Carlos III (grant
numbers PI11/00245 & PI14CIII/00011 to SR and PI12/00019 to AAM). MAJS is
supported by a contract of “Instituto de Salud Carlos III” (grant number
CD13/00013).
Author details
1Departamento de Medicina Preventiva y Salud Pública, Facultad de Ciencias
de la Salud, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain. 2Unidad
de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto
de Salud Carlos III, Majadahonda, Madrid, Spain. 3Université de Bordeaux,
INSERM U657, Pharmaco-épidémiologie et évaluation de l’impact des
produits de santé sur les populations, F-33000 Bordeaux cedex, France.
4Departamento de Medicina, Universidad del País Vasco UPV/EHU,
Vitoria-Gasteiz, Spain. 5Servicio de Urgencias, Hospital Universitario de Araba,
Vitoria-Gasteiz, Spain. 6Chair of Statistics, University of Goettingen, 37073
Göttingen, Germany. 7Centro Nacional de Microbiología, Instituto de Salud
Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2,
28220 Majadahonda, Madrid, Spain.
Received: 14 July 2015 Accepted: 29 February 2016
References
1. Montes-de-Oca M, Blanco MJ, Marquez M, Soto MJ, Fernandez-Gutierrez C,
Rodriguez-Ramos C, et al. Haemodynamic derangement in human
immunodeficiency virus-infected patients with hepatitis C virus-related
cirrhosis: the role of bacterial translocation. Liver Int. 2011;31(6):850–8.
doi:10.1111/j.1478-3231.2011.02505.x.
2. Younossi ZM, Stepanova M, Mishra A, Venkatesan C, Henry L, Hunt S. The
impact of chronic hepatitis C on resource utilisation and in-patient mortality
for Medicare beneficiaries between 2005 and 2010. Aliment Pharmacol Ther.
2013;38(9):1065–75. doi:10.1111/apt.12485.
3. Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, et al. Liver
stiffness is associated with risk of decompensation, liver cancer, and death
in patients with chronic liver diseases: a systematic review and meta-
analysis. Clin Gastroenterol Hepatol. 2013;11(12):1573–84. e1-2; quiz e88-9.
doi:10.1016/j.cgh.2013.07.034.
4. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes
mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1S):S69–78.
doi:10.1016/j.jhep.2014.08.003.
5. van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S,
et al. Is there sufficient evidence to recommend antiviral therapy in
hepatitis C? J Hepatol. 2014;60(1):191–6. doi:10.1016/j.jhep.2013.07.043.
6. Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med.
2011;364(13):1272–4. doi:10.1056/NEJMe1100829.
7. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, et al.
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med.
2013;369(7):630–9. doi:10.1056/NEJMoa1213557.
8. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response
in hepatitis C: a systematic review of the clinical, economic and quality of
life benefits. BMC Infect Dis. 2015;15(1):19. doi:10.1186/s12879-015-0748-8.
9. McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Hayes P, Dillon JF, et al. Excess
morbidity in the hepatitis C-diagnosed population in Scotland, 1991-2006.
Epidemiol Infect. 2011;139(3):344–53. doi:10.1017/S0950268810001421.
10. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis
and death: analysis of the National Hospital Discharge Survey. Chest.
2003;124(3):1016–20.
11. Gildea TR, Cook WC, Nelson DR, Aggarwal A, Carey W, Younossi ZM, et al.
Predictors of long-term mortality in patients with cirrhosis of the liver
admitted to a medical ICU. Chest. 2004;126(5):1598–603. doi:10.1378/
chest.126.5.1598.
12. Olson JC, Wendon JA, Kramer DJ, Arroyo V, Jalan R, Garcia-Tsao G, et al.
Intensive care of the patient with cirrhosis. Hepatology. 2011;54(5):1864–72.
doi:10.1002/hep.24622.
13. Gustot T, Felleiter P, Pickkers P, Sakr Y, Rello J, Velissaris D, et al. Impact of
infection on the prognosis of critically ill cirrhotic patients: results from a
large worldwide study. Liver Int. 2014;34(10):1496–503. doi:10.1111/liv.12520.
14. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in
cirrhosis. Hepatology. 2009;50(6):2022–33. doi:10.1002/hep.23264.
Álvaro-Meca et al. BMC Infectious Diseases  (2016) 16:122 Page 8 of 9
15. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial
infections in cirrhosis: a position statement based on the EASL Special
Conference 2013. J Hepatol. 2014;60(6):1310–24. doi:10.1016/j.jhep.2014.01.024.
16. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E,
et al. Patients with acute on chronic liver failure display “sepsis-like” immune
paralysis. J Hepatol. 2005;42(2):195–201. doi:10.1016/j.jhep.2004.10.019.
17. Lin CY, Tsai IF, Ho YP, Huang CT, Lin YC, Lin CJ, et al. Endotoxemia
contributes to the immune paralysis in patients with cirrhosis. J Hepatol.
2007;46(5):816–26. doi:10.1016/j.jhep.2006.12.018.
18. Saliba F, Ichai P, Levesque E, Samuel D. Cirrhotic patients in the ICU:
prognostic markers and outcome. Curr Opin Crit Care. 2013;19(2):154–60.
doi:10.1097/MCC.0b013e32835f0c17.
19. Subdirección General de Desarrollo. Instituto Nacional de Salud. Ministerio
de Sanidad y Consumo [http://www.ingesa.msc.es/estadEstudios/
documPublica/CMBD-2001.htm] Conjunto Mínimo Básico de Datos
Hospitales de Insalud 2001. 2001. Accessed November 1, 2015.
20. Alkaline Software Inc. The Web’s Free 2014 Medical Coding Reference.
2010 ICD-9-CM Diagnosis Codes. http://www.icd9data.com/. Accessed
November 1, 2015.
21. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR.
Epidemiology of severe sepsis in the United States: analysis of incidence,
outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–10.
22. Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology:
possibilities and pitfalls. Int J Epidemiol. 2012. doi:10.1093/ije/dyr213.
23. R Core Team. R: a language and environment for statistical computing.
Vienna, Austria. 2012.
24. Belitz C, Brezger A, Kneib T, Lang S, Umlauf N. BayesX–Software for Bayesian
inference in structured additive regression models. Version 2.1. Available
from: http://www.statistik.lmu.de/~bayesx/bayesx.html. Accessed November
1, 2015.
25. Boone MD, Celi LA, Ho BG, Pencina M, Curry MP, Lior Y, et al. Model for
End-Stage Liver Disease score predicts mortality in critically ill cirrhotic
patients. J Crit Care. 2014;29(5):881. e7-13. doi:10.1016/j.jcrc.2014.05.013.
26. Tu KH, Jenq CC, Tsai MH, Hsu HH, Chang MY, Tian YC, et al. Outcome
scoring systems for short-term prognosis in critically ill cirrhotic patients.
Shock. 2011;36(5):445–50. doi:10.1097/SHK.0b013e31822fb7e2.
27. Das V, Boelle PY, Galbois A, Guidet B, Maury E, Carbonell N, et al. Cirrhotic patients
in the medical intensive care unit: early prognosis and long-term survival. Crit
Care Med. 2010;38(11):2108–16. doi:10.1097/CCM.0b013e3181f3dea9.
28. Galbois A, Aegerter P, Martel-Samb P, Housset C, Thabut D, Offenstadt G, et
al. Improved prognosis of septic shock in patients with cirrhosis: a
multicenter study*. Crit Care Med. 2014;42(7):1666–75. doi:10.1097/
CCM.0000000000000321.
29. Pan HC, Jenq CC, Tsai MH, Fan PC, Chang CH, Chang MY, et al. Scoring
systems for 6-month mortality in critically ill cirrhotic patients: a prospective
analysis of chronic liver failure–sequential organ failure assessment score
(CLIF-SOFA). Aliment Pharmacol Ther. 2014;40(9):1056–65. doi:10.1111/
apt.12953.
30. Bao Q, Wang B, Yu L, Weng H, Ge J, Li L. A modified prognostic score for
critically ill patients with cirrhosis: an observational study. J Gastroenterol
Hepatol. 2015. doi:10.1111/jgh.13076.
31. McPhail MJ, Shawcross DL, Abeles RD, Chang A, Patel V, Lee GH, et al.
Increased survival for patients with cirrhosis and organ failure in liver
intensive care and validation of the chronic liver failure-sequential organ
failure scoring system. Clin Gastroenterol Hepatol. 2015;13(7):1353–60. e8.
doi:10.1016/j.cgh.2014.08.041.
32. Bruns T, Zimmermann HW, Stallmach A. Risk factors and outcome of
bacterial infections in cirrhosis. World J Gastroenterol. 2014;20(10):2542–54.
doi:10.3748/wjg.v20.i10.2542.
33. Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et
al. Infections in patients with cirrhosis increase mortality four-fold and
should be used in determining prognosis. Gastroenterology.
2010;139(4):1246–56. 56 e1-5. doi:10.1053/j.gastro.2010.06.019.
34. Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, et
al. Acute-on-chronic liver failure: current concepts on definition,
pathogenesis, clinical manifestations and potential therapeutic
interventions. Expert Rev Gastroenterol Hepatol. 2011;5(4):523–37. quiz 37.
doi:10.1586/egh.11.47.
35. Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D, et al.
Septic shock in patients with cirrhosis: hemodynamic and metabolic
characteristics and intensive care unit outcome. Crit Care Med. 1992;20(6):746–50.
36. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol.
2014;61(1 Suppl):S58–68. doi:10.1016/j.jhep.2014.07.012.
37. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes
mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1 Suppl):S69–78.
doi:10.1016/j.jhep.2014.08.003.
38. Heim MH, Thimme R. Innate and adaptive immune responses in HCV
infections. J Hepatol. 2014;61(1 Suppl):S14–25. doi:10.1016/j.jhep.2014.06.035.
39. Shen HN, Lu CL, Yang HH. Epidemiologic trend of severe sepsis in Taiwan from
1997 through 2006. Chest. 2010;138(2):298–304. doi:10.1378/chest.09-2205.
40. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the
United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546–54.
doi:10.1056/NEJMoa022139.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Álvaro-Meca et al. BMC Infectious Diseases  (2016) 16:122 Page 9 of 9
